Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary Hypertension AND Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    730 result(s) found for: Secondary Hypertension AND Hypertension. Displaying page 9 of 37.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2018-001727-39 Sponsor Protocol Number: POP03 Start Date*: 2018-10-16
    Sponsor Name:Polpharma S.A.
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSSOVER, COMPARATIVE, NON-INFERIORITY TRIAL EVALUATING THE EFFICACY AND TOLERABILITY OF GENERIC LATANOPROST 0.05 MG/ML EYE DROPS SOLUTIO...
    Medical condition: Ocular hypertension and open angle glaucoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-004307-14 Sponsor Protocol Number: BECRO/ACT/LATANOS Start Date*: 2021-02-12
    Sponsor Name:actrevo GmbH
    Full Title: Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost 0.05 mg/mL eye drops...
    Medical condition: Open angle glaucoma or ocular hypertension Elevated IOP and paediatric glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002844-24 Sponsor Protocol Number: H6D-MC-LVGX Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Double-Blind, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003387-27 Sponsor Protocol Number: 848300145/0129/1POP04 Start Date*: 2021-11-02
    Sponsor Name:Pharmaceutical Works Polpharma S.A. (Polpharma S. A.)
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSS-OVER, COMPARATIVE, NON-INFERIORITY TRIAL OF GENERIC LATANOPROST + TIMOLOL (50μG + 5MG)/ML EYE DROPS, SOLUTION (POLPHARMA S.A.) COMPA...
    Medical condition: Ocular hypertension and open angle glaucoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-005008-16 Sponsor Protocol Number: STOPPIT-01 Start Date*: 2021-03-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial
    Medical condition: Liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    20.1 10021881 - Infections and infestations 10051156 Ascites infection LLT
    20.0 10021881 - Infections and infestations 10068547 Bacterascites PT
    20.0 10021881 - Infections and infestations 10068555 Monomicrobial non-neutrocytic bacterascites LLT
    24.1 10021881 - Infections and infestations 10061135 Spontaneous bacterial peritonitis PT
    21.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003060-25 Sponsor Protocol Number: MEIN/22/NeRam-Hyp/001 Start Date*: 2023-03-07
    Sponsor Name:Menarini International Operations Luxembourg SA
    Full Title: Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA ...
    Medical condition: Cardiovascular Disease Hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-003816-21 Sponsor Protocol Number: RDG-10298 Start Date*: 2012-01-11
    Sponsor Name:S.A. Alcon-Couvreur N.V
    Full Title: Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimat...
    Medical condition: Open angle Glaucoma Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024332-42 Sponsor Protocol Number: BAY63-2521/13605 Start Date*: 2014-04-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon...
    Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003186-24 Sponsor Protocol Number: 192024-092 Start Date*: 2015-04-23
    Sponsor Name:Allergan Limited
    Full Title: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
    Medical condition: Open-angle Glaucoma and Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Trial now transitioned) IT (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019483-37 Sponsor Protocol Number: PelleLindqvist Start Date*: 2011-04-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Vitamin D supplementation for prevention of placenta mediated pregnancy complications.
    Medical condition: We will try to prevent preeclampsia, groth restriction and prematurity by vitamin D supplementation given as one dose in mid pregnancy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036485 Pre-eclampsia LLT
    12.1 10036590 Premature baby LLT
    12.1 10053759 Growth retardation LLT
    Population Age: Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000774-70 Sponsor Protocol Number: CVEA489A2302 Start Date*: 2006-09-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlo...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001544-26 Sponsor Protocol Number: RASCOVID-19 Start Date*: 2020-04-22
    Sponsor Name:Center for Clinical Metabolic Research, Gentofte Hospital
    Full Title: Effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10005747 Blood pressure high LLT
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011157-41 Sponsor Protocol Number: LT2345-PIII-12/08 Start Date*: 2009-07-24
    Sponsor Name:laboratoires théa
    Full Title: Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients. Phase III study, multicentre, international, randomised, investigator-m...
    Medical condition: The study population is suffering from glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018304 Glaucoma LLT
    9.1 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002750-38 Sponsor Protocol Number: C-08-09 Start Date*: 2008-10-22
    Sponsor Name:Alcon Research Ltd
    Full Title: 24-hour IOP control with Travoprost / Brinzolamide fixed combination once-daily (QD)in the evening vs TRAVATAN
    Medical condition: Open-angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    9.1 10030348 Open angle glaucoma LLT
    9.1 10030043 Ocular hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005091-42 Sponsor Protocol Number: 192024-041D Start Date*: 2012-05-08
    Sponsor Name:Allergan Limited
    Full Title: An Open Label (Stage 1) and Randomized (Stage 2), 24-Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension
    Medical condition: open-angle glaucoma (OAG) and ocular hypertension (OHT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003423-21 Sponsor Protocol Number: IK-7002-COPD-006 Start Date*: 2014-09-29
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group...
    Medical condition: Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022984-36 Sponsor Protocol Number: 201051 Start Date*: Information not available in EudraCT
    Sponsor Name:Santen Oy
    Full Title: A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to ...
    Medical condition: Patients diagnosed with ocular hypertension or open-angle glaucoma (primary open-angle glaucoma [POAG], capsular glaucoma or pigmentary glaucoma).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030043 Ocular hypertension LLT
    12.1 10036719 Primary open angle glaucoma LLT
    12.1 10035015 Pigmentary glaucoma LLT
    12.1 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) ES (Completed) PT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002235-25 Sponsor Protocol Number: A1481131 Start Date*: 2006-12-14
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.0 10064911 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) SK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004890-15 Sponsor Protocol Number: EU-C-001-II-01 Start Date*: 2019-06-05
    Sponsor Name:Eustralis Pharmaceuticals Ltd.
    Full Title: A double-blind placebo-controlled study with an open-label pilot phase, assessing the efficacy, tolerability and safety of EU-C-001 in patients with moderate to severe traumatic brain injury
    Medical condition: Traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10021665 Increased intracranial pressure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-024512-34 Sponsor Protocol Number: C-10-040 Start Date*: 2011-05-17
    Sponsor Name:Alcon Research, Ltd.
    Full Title: Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/ml / Brimonidine 2 mg/ml Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/ml Eye Drops, Suspension and Brimonidine 2 mg/...
    Medical condition: Open-angle glaucoma and ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10030856 Open-angle glaucoma LLT
    14.1 100000004853 10020784 Hypertension ocular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) LV (Completed) DE (Completed) HU (Completed) LT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:50:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA